source
- Actinogen’s Alzheimer’s drug Xanamem fails pivotal trial, shares plunge over 80%Actinogen Medical, an Australian biotech, reported that its only candidate, Xanamem (emestedastat), did not meet the primary endpoint in a Phase 2b/3 study in patients with mild to moderate Alzheim…
- FDA puts drug repurposing front-and-center, says BioSpace podcastIn a recent episode of BioSpace’s podcast “Denatured,” host Jennifer C. Smith-Parker spoke with Daniel Tillett, chief executive of Racura Oncology, and Sten Sörensen, chief executive of Cereno Scie…